Ultragenyx Pharmaceutical
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ultragenyx Pharmaceutical sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).
Ultragenyx Pharmaceutical: 52 sponsored US clinical trials, 4 recruiting.
Ultragenyx Pharmaceutical sponsors 52 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 25 completed. 9 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), with 3 trials.
Top-decile sponsor footprint
Ultragenyx Pharmaceutical ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 38 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (65.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
52 total, page 2 of 2
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
NCT01406548
Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
NCT01417091
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 15 |
| Phase 3 | 9 |
Therapeutic Areas
What is open in the Ultragenyx Pharmaceutical pipeline
4 recruiting of 52 indexed (8% open); 25 completed (48%).
Phase mix: 9 late (III/IV) vs 24 early (I/II) (early-phase heavy).
Top condition: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ultragenyx Pharmaceutical: open-pipeline peers nationwide
Peers matched on 52 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Ultragenyx Pharmaceutical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 52 trials (± recruiting share)
- Albany Medical College · 52 trials · 13% recruiting
- Burzynski Research Institute · 52 trials · 0% recruiting
- Dr. Reddy's Laboratories Limited · 52 trials · 0% recruiting
- PTC Therapeutics · 52 trials · 2% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this Ultragenyx Pharmaceutical page
52 registered trials is a research-attention snapshot, not an endorsement of Ultragenyx Pharmaceutical or any single study.
- 4 of Ultragenyx Pharmaceutical's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) is the condition Ultragenyx Pharmaceutical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ultragenyx Pharmaceutical pipeline card: 52 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.